Nangibotide治疗感染性休克患者:一项2a期随机对照临床试验
这项多中心随机双盲两阶段研究纳入49例感染性休克患者,在休克发作后24小时内开始持续输注Nangibotide(0.3、1.0或3.0 mg/kg/h)或安慰剂,最长5天。主要安全性终点为不良事件(无论严重与否)和死亡,至第28天收集治疗期不良事件(TEAEs)。结果显示各组TEAEs无显著差异,无因TEAE停药,未出现抗药抗体;Nangibotide药代动力学呈剂量比例关系且清除率与剂量无关。探索性终点方面,Nangibotide未显著影响药效学标志物;汇总Nangibotide组与安慰剂比较,随机人群中SOFA评分从基线至第5天的最小二乘均值变化(±SE)为-0.7(±0.85),高基线血浆sTREM-1浓度患者中为-1.5(±1.12),均无统计学显著性,器官支持终点呈相似模式。结论认为结果鼓励进一步评估Nangibotide并探索血浆sTREM-1浓度作为预测性疗效生物标志物。
要点
- 49例感染性休克患者随机接受Nangibotide 0.3、1.0或3.0 mg/kg/h持续输注或安慰剂,休克发作后<24小时开始,最长5天。
- 至第28天收集的TEAEs在各治疗组间无显著差异,无因TEAE停药,未报告抗药抗体出现。
- Nangibotide药代动力学呈剂量比例关系,清除率与剂量无关。
- Nangibotide未显著影响药效学标志物;汇总Nangibotide组 vs 安慰剂SOFA评分第5天较基线变化为-0.7(±0.85),高基线sTREM-1患者中为-1.5(±1.12),均无统计学显著性。
- 作者认为结果鼓励进一步评估Nangibotide并进一步探索血浆sTREM-1浓度作为预测性疗效生物标志物。
适用人群与场景
- 感染性休克患者,休克发作后24小时内开始治疗。
处置流程与药物剂量
- Nangibotide以0.3、1.0或3.0 mg/kg/h持续静脉输注,休克发作后<24小时开始,持续最长5天。
研究设计与关键结果
- 多中心随机双盲两阶段研究,49例感染性休克患者随机接受Nangibotide(0.3、1.0或3.0 mg/kg/h)持续输注或安慰剂,休克发作后<24小时开始,最长5天。
- 主要安全性终点为不良事件(无论严重与否)和死亡;至第28天收集所有TEAEs,各治疗组间无显著差异,无因TEAE停药,未报告抗药抗体出现。
- Nangibotide药代动力学呈剂量比例关系,清除率与剂量无关。
- Nangibotide未显著影响药效学标志物。
- 汇总Nangibotide组 vs 安慰剂SOFA评分从基线至第5天最小二乘均值变化(±SE):随机人群中为-0.7(±0.85),高基线血浆sTREM-1浓度患者中为-1.5(±1.12),均无统计学显著性;器官支持终点呈相似模式。
证据类型、等级与局限
- 证据类型:2a期多中心随机双盲两阶段临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为结果鼓励进一步评估Nangibotide,并进一步探索血浆sTREM-1浓度作为预测性疗效生物标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients.
METHODS: This was a multicenter randomized, double-blind, two-stage study. Patients received either continuous infusion of nangibotide (0.3, 1.0, or 3.0 mg/kg/h) or placebo. Treatment began < 24 h after shock onset and continued for up to 5 days. Safety primary outcomes were adverse events (AEs), whether serious or not, and death. Exploratory endpoints evaluated nangibotide effects on pharmacodynamics, organ function, and mortality, and were analyzed according to baseline sTREM-1 concentrations.
RESULTS: Forty-nine patients were randomized. All treatment emergent AEs (TEAEs) were collected until Day 28. No significant differences were observed in TEAEs between treatment groups. No drug withdrawal linked to TEAE nor appearance of anti-drug antibodies were reported. Nangibotide pharmacokinetics appeared to be dose-proportional and clearance was dose-independent. Nangibotide did not significantly affect pharmacodynamic markers. Decrease in SOFA score LS mean change (± SE) from baseline to Day 5 in pooled nangibotide groups versus placebo was - 0.7 (± 0.85) in the randomized population and - 1.5 (± 1.12) in patients with high baseline plasma sTREM-1 concentrations (non-significant). This pattern was similar to organ support end points.
CONCLUSION: No significant increases in TEAEs were detected in nangibotide-treated patients versus placebo. These results encourage further evaluation of nangibotide and further exploration of plasma sTREM-1 concentrations as a predictive efficacy biomarker.
参考来源
- François B, Wittebole X, Ferrer R, et al. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. Intensive Care Med. 2020. PMID: 32468087. doi:10.1007/s00134-020-06109-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。